IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice
Metrics: PDF 1475 views | HTML 1990 views | ?
Mian Xie1,*, Xiao-jun Wu2,3,*, Jin-jun Zhang4, Chao-sheng He5,*
1China State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2State Key Laboratory of Oncology in Southern China, Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
3Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
4Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
5Department of Internal Medicine, Guangdong General Hospital, Guangzhou, China
*These authors have contributed equally to this work
Mian Xie, e-mail: [email protected]
Keywords: lung cancer, IL13Rα2, TAZ, PI3K
Received: May 15, 2014 Accepted: September 08, 2015 Published: September 21, 2015
IL-13 receptor subunit alpha-2 (IL13Rα2) is associated with poor prognosis in some cancers. However, the role of IL13Rα2 in lung cancer remains unknown. We showed that IL13Rα2 overexpression was associated with late stages of disease progression and shorter disease-free survival (DFS) as well as overall survival (OS) in resected lung cancer patients. IL13Rα2 promoted the migration, invasion and anoikis resistance of lung cancer cells in vitro. Silencing of IL13Rα2 in lung cancer cells decreased invasion in vitro and lung metastasis in vivo. IL13Rα2 activated phosphatidylinositol 3 kinase (PI3K), Akt, and transcriptional coactivator with PDZ-binding motif (TAZ). Inhibition of PI3K attenuated activation of TAZ and its downstream target genes by IL13Rα2. We suggest that inhibition of IL13Rα2 is a potential therapeutic approach in lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.